Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $3.5552W HIGH $6.15
Volume
13.62 K
Value Traded
300.40 K
Short % Float
0.51%
Days to Cover
1.0
+1.76%Week
-3.98%1 Month
+2%3 Month
+3.7%6 Month
+2.07%5 Year
-99.77%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
47.68 M
EPS (TTM)
-0.33
P/E Ratio
-
Ent. Value
39.75 M
Total Shares
10.97 M
Float Shares
7.95 M
Insiders
27.59%
Institutions
33.32%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
POCI Catalyst Timeline
Dated clinical, regulatory and corporate events for Precision Optics Corporation, Inc.
Past FDA Catalysts and PDUFA Decisions
How POCI actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Precision Optics Corporation, Inc. is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every POCI program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| COLL WAYNE MOfficer (Chief Financial Officer) | Grant/Award | 1,568 36,807 held | $3.99 | 03/31/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in POCI
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in POCI for Q2 2026. | ||||
POCI Institutional Ownership Trends
POCI Short Interest
Shares sold short, counted twice a month.
0.51%
Short % of Float
of tradable shares sold short
40.5K
Shares Sold Short
+478.9% vs prior count
1.0 Low
Days to Cover
trading days of normal volume to buy every short share back
111.4K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How POCI ranks across every disease it competes in
Competitive Position is a premium feature
See how POCI ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialPOCI News
POCI▼ -5.6%on this news
Precision Optics to Participate in the Lytham Partners Fall 2026 Investor Conference
Precision Optics Corporation will participate in the Lytham Partners Fall 2026 Investor Conference, taking place virtually on September 29-30, 2026. The company will host a webcast presentation and one-on-one meetings with investors. This engagement highlights Precision Optics' commitment to investor relations and showcases its advanced optical technologies.
Read more →POCI▼ -5.6%on this newsshared move
Precision Optics Reports Fourth Quarter and Fiscal Year 2026 Financial Results
Precision Optics Corporation reported strong financial results for Q4 and FY 2026, achieving record revenues and significant growth in production revenue. The company experienced a notable improvement in Adjusted EBITDA, marking a positive trend. However, guidance for FY 2027 suggests a temporary pause in demand from a key customer, which may impact future revenue. The leadership team is focused on expanding capabilities and market penetration to offset these challenges.
Read more →POCIPrecision Optics Schedules Fourth Quarter and Fiscal Year 2026 Conference Call for September 28, 2026
Precision Optics Corporation has announced a conference call to discuss its fourth quarter and full year fiscal 2026 financial results, scheduled for September 28, 2026. The company will release its financial results and file its 10-K after market close on the same day. Interested parties can join the call via phone or live webcast.
Read more →POCIPrecision Optics Announces Initial Engineering Order from New Satellite Optical Communications Customer
Precision Optics Corporation has announced an initial $50,000 development order from a U.S. space technology company for laser communication subassemblies. This order is part of early engineering work for Optical Communication Terminals on the customer's satellite systems. The company aims to finalize a comprehensive engineering agreement and transition to production within the next year.
Read more →POCIPrecision Optics Announces Receipt of $1.3 Million Follow-On Production Orders from Large Defense Company
Precision Optics Corporation announced the receipt of $1.3 million in follow-on production orders from a major U.S. defense contractor. This order supports ongoing production of complex optical assemblies developed since 2018. The company anticipates negotiating a long-term manufacturing agreement to enhance production efficiency and continuity. This development positions Precision Optics favorably in the defense and aerospace markets.
Read more →POCIPrecision Optics Appoints Peter Thier as Senior Vice President of Sales and Marketing
Precision Optics Corporation has appointed Peter Thier as Senior Vice President of Sales and Marketing. Thier, who has over 30 years of experience in the medical technology sector, will lead the company's sales and marketing strategy. His expertise is expected to enhance the company's growth and strengthen its market position.
Read more →POCIPrecision Optics to Participate in the Lytham Partners 2026 Consumer & Technology Investor Summit on August 18, 2026
Precision Optics Corporation will participate in the Lytham Partners 2026 Consumer & Technology Investor Summit on August 18, 2026. The event will be held virtually, with a webcast available for attendees. This participation underscores the company's focus on advanced optical instruments for medical and defense/aerospace industries.
Read more →POCIPrecision Optics to Present at the Planet MicroCap Las Vegas 2026 Investor Conference on June 17, 2026
Precision Optics Corporation will present at the Planet MicroCap Las Vegas 2026 Investor Conference on June 17, 2026. The presentation will take place at the Bellagio Resort & Hotel at 11:00 a.m. Pacific time. The company will also hold investor meetings during the conference, emphasizing its focus on advanced optical instruments for medical and defense/aerospace industries.
Read more →POCI▲ +6.5%on this news
Precision Optics to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026
Precision Optics Corporation will participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026. The event will feature a webcast presentation and virtual one-on-one meetings with investors. This participation aims to enhance investor relations and showcase the company's advanced optical technologies for medical and defense/aerospace applications.
Read more →POCIPrecision Optics Reports Third Quarter Fiscal Year 2026 Financial Results
Precision Optics Corporation reported impressive financial results for the third quarter of fiscal year 2026, with revenues reaching a record $8.7 million, an increase of 108% year-over-year. The company also saw significant improvements in gross margins, up to 23.6%, and achieved positive adjusted EBITDA of $0.3 million. Their strong performance is driven by increased production in key segments and a major follow-on order in the ophthalmic program. Additionally, the company raised its revenue guidance for the fiscal year, forecasting continued growth.
Read more →POCIPrecision Optics Schedules Third Quarter of Fiscal Year 2026 Conference Call for May 13, 2026
Precision Optics Corporation has announced a conference call for May 13, 2026, to discuss its third quarter financial results for fiscal year 2026. The call will follow the release of the company's 10-Q filing after the market closes. Interested parties can join via phone or live webcast, with a replay available for seven days.
Read more →POCI▲ +8.7%on this newsshared move
Precision Optics Announces Receipt of $3.5 Million Follow-On Production Order for Single-Use Ophthalmic Program
Precision Optics Corporation has received a $3.5 million follow-on production order for its single-use ophthalmic endoscope from a global medical device company. This order marks the company's second single-use program entering production, expected to be fulfilled over the next 12 to 15 months. The initiative is a result of over five years of joint development and aims to replace existing reusable systems.
Read more →POCIPrecision Optics Corporation, Inc. Announces Pricing of Upsized $10 Million Public Offering of Common Stock
Precision Optics Corporation announced the pricing of its upsized public offering of 2,777,777 shares at $3.60 per share. The offering, which is oversubscribed, includes participation from company executives. The net proceeds will be used for working capital and general corporate purposes, with the offering expected to close on March 30, 2026.
Read more →POCI▼ -6.2%on this newsshared move
Precision Optics Corporation, Inc. Announces Proposed Public Offering of Common Stock
Precision Optics Corporation, Inc. has announced a proposed public offering of common stock, aimed at raising capital. The offering is underwritten by Lucid Capital Markets and is subject to market conditions. A preliminary prospectus will be filed with the SEC, but there are uncertainties regarding the offering's completion and terms.
Read more →POCIPrecision Optics Reports Second Quarter Fiscal Year 2026 Financial Results
Precision Optics Corporation reported impressive financial results for its second quarter of fiscal year 2026, with revenue reaching a quarterly record of $7.4 million, marking a 63% increase year-over-year. The production segment was particularly strong, achieving a remarkable 105% growth. However, the company also faced challenges, reporting a net loss that widened compared to the same quarter last year and significant declines in gross margins. Forward-looking statements indicate expectations for continued revenue growth and operational improvements in the latter half of the fiscal year.
Read more →POCI▼ -5.7%on this newsshared move
Precision Optics Schedules Second Quarter of Fiscal Year 2026 Conference Call for February 17, 2026
Precision Optics Corporation has announced a conference call to discuss its second quarter financial results for fiscal year 2026, scheduled for February 17, 2026. The call will follow the release of its financial results and the filing of its 10-Q. Interested parties can join via phone or a live webcast.
Read more →POCIPrecision Optics Reports First Quarter Fiscal Year 2026 Financial Results
Precision Optics Corporation (POCI) reported a record $6.7 million in revenue for the first quarter of fiscal year 2026, marking a 59% increase from the same quarter last year. The company highlighted significant production growth, particularly in aerospace components, although it also experienced a net loss of $(1.6) million, which is greater than the loss reported in the previous year. Although gross margins have fallen, the company's guidance for FY 2026 projects revenue growth exceeding $25 million and an improvement in Adjusted EBITDA. Key development contracts for advanced optical systems indicate a strong market position and continued demand.
Read more →POCI▲ +17.5%on this newsshared move
Precision Optics Announces Product Development Agreement to Develop Custom High-End Borescope for Jet Engines
Precision Optics Corporation has secured a $678,000 product development order to create a next-generation borescope for inspecting jet engines. This high-end system will feature advanced imaging capabilities and is designed to endure harsh conditions. The order reflects the company's competitive edge in the aerospace sector and their commitment to innovative optical solutions.
Read more →POCIPrecision Optics Announces Product Development Agreement to Deliver Next-Generation Augmented Reality Sub-Systems for Fighter Pilots
Precision Optics Corporation has announced a product development agreement to create augmented reality sub-systems for US Air Force fighter pilots. The initial order, valued at $723,000, focuses on designing compact optical systems that enhance in-air training. This initiative reflects the increasing interest in AR technologies within the defense sector, particularly for pilot training. The global market for aviation AR is expected to expand at a CAGR exceeding 20% from 2023 to 2030.
Read more →POCIPrecision Optics Schedules First Quarter of Fiscal Year 2026 Conference Call for November 13, 2025
Precision Optics Corporation has announced a conference call to discuss its financial results for the first quarter of fiscal year 2026, scheduled for November 13, 2025. The company will release its financial results and file its 10-Q after market close on the same day. Interested parties can join the call via phone or a live webcast.
Read more →About Precision Optics Corporation, Inc.
Headquarters550 KING STREET,, LITTLETON, MA, 01460
BIOPHARMAWATCH ELITE PLUS
Trade the next POCI catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime